Tag: Lapatinib

Current international guidelines recommend a combination of perioperative chemotherapy and surgery in the treatment of operable gastroesophageal cancer. However, given high mortality rates in patients treated with contemporary perioperative chemotherapy, more clinically efficacious and less toxic regimens are needed. One potential strategy involves combining anti-HER2 agents, such as lapatinib,...
Association Between Preoperative Opioid and Benzodiazepine Prescription Patterns and Mortality After Noncardiac Surgery Strategies to amend clinician prescription patterns are of critical importance in addressing opioid abuse and opioid-related deaths across the United States. One potential approach involves targeting opioid-prescription practices in the perioperative period. However, little is known about...
Image: PD 1. HLA-DRB1*07:01 and HLA-DQA1*02:01 are strongly associated with liver injury among patients with HER2+ primary breast cancer taking lapatinib. Evidence Rating Level: 1 (Excellent) Study Rundown: Lapatinib, a dual HER2/neu and EGFR inhibitor, is used as part of combination therapy for advanced or metastatic HER2-expressing breast cancer. Though previously well-tolerated,...